

# Medical AI Solution Platform

EASY WAY TO MEET AI

## 01. Company Overview

### Connecting AI and Care for a Healthier, Happier Life

Through our platform, we bring medical AI closer to people and healthcare providers.

#### Company Information

|               |                                                                    |
|---------------|--------------------------------------------------------------------|
| Company Name  | maihub Corp.                                                       |
| Address       | 4F, 58, Baumoe-ro 37-gil, Seocho-gu, Seoul, Republic of Korea      |
| Established   | June 9, 2022                                                       |
| Capital       | USD 72,000 <i>(KRW 103.12 million, based on 1 USD = 1,430 KRW)</i> |
| Par Value     | USD 0.70 <i>(KRW 1,000 per share)</i>                              |
| Issued Shares | 103,122 shares                                                     |
| Business Area | Development and service of AI-based medical solutions              |
|               | Medical AI Platform Service                                        |

#### Our Team

Composed of top experts in **medical AI service**



**CEO** Hyuck Yang

- STOP-TB Steering Committee
- Head of Imaging SW Development, VUNO Inc.
- Director, R&D Center, Rayence Co., Ltd.
- Team Lead, Ultrasound Research Lab, Siemens Korea
- M.S. in Computer Science, Soongsil University



**CTO** Sang-Ki Kim

- Director, R&D Center, Vuno Inc.
- Senior Researcher, AI Research Lab, LG Corp.
- Ph.D. in Computer Science, POSTECH



**CBO** Jonghyun Kim

- Head of Business Division, JLK Inc.
- Head of Domestic Sales Division, VUNO Inc.
- Business Manager, Hanmi Pharm. Co., Ltd.
- B.A. in Business Administration, Hanyang University

02. Company History

maihub is committed to enabling **easier and more efficient adoption of medical AI** in clinical practice.

1<sup>st</sup>

Korea's first AI platform

20<sup>+</sup>

Integrated AI Solutions

Trusted by

1000<sup>+</sup>

Hospitals and clinics in Korea

30<sup>+</sup>

Registered Patents

History

2022 | Foundation

- 2022.06 Established maihub Corp.
- 2022.10 Founded R&D Center
- 2022.11 Registered mailink as a medical device
- 2022.11 Secured seed investment (USD 210K)

2023 | Growth Stage

- 2023.03 Selected for the Credit Guarantee Fund's Innovative Startup Growth Support Program (USD 690K)
- 2023.05 Selected for '23 Initial Startup Package Project'
- 2023.07 Acquired GMP Certification
- 2023.08 Obtained MFDS approval for InsightVue
- 2023.09 Secured Pre-A Funding (USD 350K)
- 2023.11 Obtained ISO13485:2016 Certification
- 2023.11 Certified as a Venture Business

2024 ~ Present | Expansion

- 2024.03 Obtained Malaysia MDA certification
- 2024.05 Selected for 2024 Startup Growth Package
- 2024.05 Selected for Tech Incubator Program for startup Korea(TIPS)
- 2024.07 Secured Series A investment (USD 3.0M)
- 2025.05 Secured Series A+ investment (USD 3.15M)
- 2025.07 Received the highest evaluation score in the 2024 Startup Growth Package Program
- 2025.08 Acquired Indonesia BPOM certification
- 2025.09 Acquired VUNO Bone age AI Solution

### 03. Our Partners

We collaborate with the best partners in each field.

|                              | Domestic Partners                                                                   |                                                                                     |                                                                                      |                                                                                       | Global Partners                                                                       |                                                                                       |                                                                                       |
|------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| AI Vendors                   |    |    |    |    |    |    |    |
|                              |    |    |    |    |                                                                                       |                                                                                       |                                                                                       |
|                              |    |    |    |    |                                                                                       |                                                                                       |                                                                                       |
|                              |    |    |   |    |                                                                                       |                                                                                       |                                                                                       |
| Medical Device Manufacturers |    |    |    |    |    |                                                                                       |                                                                                       |
|                              |  |  |  |  |                                                                                       |                                                                                       |                                                                                       |
| Distributors                 |  |                                                                                     |                                                                                      |                                                                                       |  |  |  |

## 04. Challenges

Although awareness of medical AI has improved, widespread adoption remains difficult.

### AI Vendors

Struggle to enter markets  
and establish distribution channels


### Medical Institutions

Difficulty securing the right AI solutions  
High implementation and maintenance costs

### Industry

Lack of understanding of AI technology  
Shortage of professionals for SaMD maintenance

**Emergence of global platform companies that integrate and deliver medical AI solutions**



## But

**Limited adoption due to interoperability and security challenges**

### Integration & Data Security Issues

Additional development and cost required for integration  
with existing PACS and EMR system

### Need for Hospital-Specific Services

Hospitals require customized AI solutions and  
tailored system configurations.


### Maintenance & Accountability Issues

Lack of clear responsibility when issues occur;  
need for prompt and transparent support.

05. ONE platform : mailink


# maiLINK

## We solve it all, in ONE Platform



## 06. maiLink (Medical AI Platform)

### Seamless Medical AI Solutions — Fully Integrated into Your Workflow



#### AI Service

##### AI Diagnosis & Prediction

- Integration with Medical Imaging Modalities
- AI Cloud Server Connectivity
- Clinical & Screening Data Integration
- Patient Consent & Data Protection

#### AI Service Management System

##### License, Credit Management & Maintenance

- Credit Usage Monitoring
- Global Cloud Service
- Error Alert System
- Auto-update SystemAI

#### Medical Data Preprocessing

##### Medical Image Optimization for AI

- Image Rotation
- Body-part Classification
- Standardization

#### AI Result

##### Optimization of AI Analysis Results

- AI Dedicated Viewer
- AI Report Generation
- PACS / EMR Integration

## 07. Key Differentiators

### Hybrid Solution Service of On-device & On-premise & Cloud suitable for Flexible Healthcare Integration

#### Easy to Adopt

- Simple Installation and user-friendly interface
- Direct connection with various medical imaging devices
- Continuous updates of the latest algorithms via Cloud service
- System for monitoring usage and managing maintenance

#### AI Integrated Platform

- Includes 17 AI Solutions
- Provides remote support and maintenance



#### Cost-Effective

- Utilization of mini-PC instead of expensive servers
- Pay only when selected/used
- No additional costs for integration with medical devices (EMR, PACS)


#### Security and Reliability

- Store medical data on-site
- Patient data encryption & anonymization
- Adoption only after verification via PoC

## 08. maiLink – Specialized AI Feature

### Improving Clinical Efficiency through maiLink's AI-Dedicated Features

#### Automated AI Report Generation



| No. | Patient ID | Patient Name | Age    | AI Result  | AI Score | Comment                                                              |
|-----|------------|--------------|--------|------------|----------|----------------------------------------------------------------------|
| 1   | ML001      | Unknown      | 68Y 5M | Abnormal   | 21.93    | Nodule(21.93)                                                        |
| 2   | ML002      | Unknown      | 74Y 5M | Abnormal   | 69.09    | Atelectasis(69.09), Nodule(27.48)                                    |
| 3   | ML003      | Unknown      | 74Y 5M | No Finding | 0.57     | [B] Scattered areas of fibroglandular density (4 of 10)              |
| 4   | ML004      | Unknown      | 74Y 5M | Abnormal   | 81.61    | [D] Extremely dense (10 of 10) / RCC(81 C), LCC(16 C), RMLO(10 C)    |
| 5   | ML005      | Unknown      | 28Y 7M | Abnormal   | 97.69    | Consolidation(97.69), Fibrosis(38.3), Pleural Effusion(65.27), Tuber |


- Automatically generates AI reading results for clinicians
- Prioritizes cases with suspected abnormalities
- Provides quick copy-and-paste functionality to speed up reporting

#### AI-Optimized Image Viewer



- Displays detected abnormalities directly on medical images
- Integrates multiple AI solutions in a unified viewer

#### Personalized Patient Service



- Delivers integrated information including AI results and diagnosis summaries
- Provides a mobile app for patient report access and management


## 09. Specialized Service – Multi-Diagnostic AI Suite

With maiLink's Multi-Diagnostic AI Suite, **multiple conditions can be analyzed through a single scan.**

### Chest X-ray AI Package

#### One Chest X-ray for Multiple Diagnoses


Detects 11 abnormalities, 3 diseases, and 2 trauma findings in a single exam



### Fundus AI Package

#### One Fundus Exam for Comprehensive Screening

Detects 4 major vision-threatening diseases, 12 abnormal conditions, and predicts cardiovascular risk from a single fundus image.




## 10. Specialized Service – Total Care Package

Enhancing hospital revenue and patient experience through AI health screening package.




### Predictive AI Solution




### Diagnostic AI Solutions

Provides over 20 AI diagnostic solutions




### AI Report

Suggests additional tests when abnormalities are detected



### AI Report Management App

Easily access and manage their AI reports via a mobile app




maireport

## 11. Business Model

Operating a subscription-based model with selectable and usage-based pricing for medical AI solutions.

### For AI Vendors

- Faster Market Access through an established hospital network
- Expanded Sales Opportunities by offering bundled AI packages tailored to hospital needs
- Simplified Integration, Greater Trust through a unified AI platform
- Provides first-line maintenance and technical support for integrated AI solutions



**maiLINK**

### Subscription Model

- Hospitals can choose only the AI solutions they need
- Flexible pricing based on AI model and usage volume
- Monthly subscription-based business model



### For Medical Institutions

- Improves diagnostic accuracy and enables early screening
- Generates additional revenue through linked follow-up tests
  - Easy deployment via mini-PC installation
  - No maintenance burden (includes continuous updates and technical support)

2025-07-28 PM 05:30:32

Studylist

mailList + Existing Hospital System

Patient ID

Accession No.

Any BodyPart

All

First Name

Middle Name

Last Name

Physician

Edit Info.

Delete

Read

Unread

| Study Checked | No. | Patient ID        | Patient Name      | Sex | Age  | Study Date          | Birthday   | Study |
|---------------|-----|-------------------|-------------------|-----|------|---------------------|------------|-------|
|               | 1   | ER20221101_125826 | ER20221101_125826 | O   | 10M  | 11-01-2022 12:58:29 | 11-01-2022 |       |
|               | 2   | DC-XR-03-000001   | DC-XR-03-000001   | O   | 0D   | 10-05-2021 11:44:49 |            | Che   |
|               | 3   | DC-XR-03-000002   | DC-XR-03-000002   | O   | 0D   | 10-05-2021 11:44:44 |            | Che   |
|               | 4   | 00000001          | MOD               | F   | 14Y  | 10-19-2008 12:25:19 | 10-19-2008 | Tho   |
|               | 5   | 00000002          | CJY               | M   | 14Y  | 10-19-2008 11:06:12 | 10-19-2008 | Tho   |
|               | 6   | 11788772290701    | Fall 6            | O   | 123Y | 01-01-2001 11:53:49 | 01-01-1900 | Tho   |
|               | 7   | 11788770003213    | Fall 6            | O   | 123Y | 01-01-2001 11:51:32 | 01-01-1900 | CT T  |
|               | 8   | D97258_11053      | Rubo DEMO         | M   | 0D   | 04-22-1997 13:10:47 |            |       |

| Study Checked | No. | Patient ID | Patient Name | Sex | Age | Study Date | Birthday | Study |
|---------------|-----|------------|--------------|-----|-----|------------|----------|-------|
|---------------|-----|------------|--------------|-----|-----|------------|----------|-------|

mailLINK

Auto refresh

Search (Patient ID & Name)

AI : Filter

All

ID00001

홍길동

2023-06-30

Consolidation(98.39%) , Fibrosis(25.01%) , Pleural Effusion(55.39%)

102909

Unknown

2022-12-02

[C] Heterogeneously Dense (6 of 10)

ER20221102\_100507

ER20221102\_100507

2022-11-02

[B] Scattered Fibroglandular Densities (4 of 10)

ER20221101\_175052

ER20221101\_175052

2022-11-01

[D] Extremely Dense (9 of 10)

ER20220504\_133240

ER20220504\_133240

2022-05-04

Consolidation(18.7%) , Nodule(16.3%)

12345

Anon

2015-10-02

Calcification(47.15%) , Nodule(98.4%)

01019400

Anonymized


2013-03-26

Atelectasis(81.95%) , Calcification(64.36%) , Cardiomegaly(64.33%) , Consolidation(94.33%) , Fibrosis(55.13%)

Total : 7

1 / 1

Count: 100

2023-06-30 15:40:52  
DX.F.홍길동


ID00001 홍길동 F 30 Y 06-30-2023 15:40:52

Idx 1

Se 1

Im 1

administrator



## Image Comments



1 - 1

## Chest X-ray Interpretation Report

Consolidation is present in the left lung, right middle and  
Fibrosis is present in the left lower zone.  
Cardiomediastinal contour appears normal.  
Pneumothorax is not seen.  
Pleural Effusion is present on the left side.

OK

EXI 215

06-30-2023 15:40:53

CHEST PA

☐ Auto refresh ↺

cby ▼

AI : Filter ▼

All ▼

🔍 Search (Patient ID &amp; Name)



ID ID00001

홍길동

📅 2023-06-30

Consolidation(98.39%) , Fibrosis(25.01%) , Pleural Effusion(55.39%)



ID 102909

Unknown

📅 2022-12-02

[C] Heterogeneously Dense (6 of 10)



ID ER20221102\_100507

ER20221102\_100507

📅 2022-11-02

[B] Scattered Fibroglandular Densities (4 of 10)



ID ER20221101\_175052

ER20221101\_175052

📅 2022-11-01

[D] Extremely Dense (9 of 10)



ID ER20220504\_133240

ER20220504\_133240

📅 2022-05-04

Consolidation(18.7%) , Nodule(16.3%)



ID 12345

Anon

📅 2015-10-02

Calcification(47.15%) , Nodule(98.4%)



ID 01019400

Anonymized

📅 2013-03-26

Atelectasis(81.95%) , Calcification(64.36%) , Cardiomegaly(64.33%) , Consolidation(94.33%) ,  
Fibrosis(55.13%)

Total : 7

◀ ◀ 1 / 1 ▶ ▶

Count: 100 ▼

CXR2 CXR2 Other 0Y 0M

Speed STD 1 X 1 IMG 1 X 1

Series 1

Patient( CXR2 , CXR2 , O , 0Y 0M ) , Study( DOC,DX , , 2022-11-1 )



1-1  
Original


Series 1000



1000-1  
Contour



1000-2  
Heatmap



1000-3  
Merged




1000-4  
Report

Series 1001



1001-1  
Report



maihub

Abnormality Score : **High 92**

- Consolidation 57  
(right upper ,right middle )
- Nodule / Mass 52  
(right middle )
- Fibrosis 30  
(right middle )
- Calcification 26  
(right middle )

Tuberculosis Score : **High 92**

Comment

Nodular opacity is present in the right middle zone.  
Consolidation is present in the right upper and right middle zones.  
Fibrosis is present in the right middle zone.  
Calcification is present in the right middle zone.  
Cardiomediastinal contour appears normal.  
Pleural Effusion or pneumothorax is not seen.  
Active Tuberculosis is suspected.

Abnormality Score : 92  
TB Analysis Score : 92  
Cardiomegaly : Low Mediastinal Widening : Low

Index : 5  
Zoom : 131%  
W : 256 , L : 127

Abnormality Score **High 92**

- Low Atelectasis
- 26** Calcification  
(right middle )
- Low Cardiomegaly
- 57** Consolidation  
(right upper ,right middle )
- 30** Fibrosis  
(right middle )
- Low Mediastinal Widening
- 52** Nodule / Mass  
(right middle )
- Low Pleural Effusion
- Low Pneumoperitoneum
- Low Pneumothorax

Tuberculosis Score **High 92**

Physician Result



Print Export

Send Copy

Reading Report

Accept

MMG2 MMG2 Female 0Y 0M

STD 1 X 1 IMG 2 X 1

Result Tools





Patient( MMG2 , MMG2 , F , 0Y 0M ) , Study( DOC.MG , BREAST CC , 2022-11-1 )

Lunit INSIGHT MMG v1.1.10.0

< 1 / 1 >


Lunit INSIGHT MMG v1.1.10.0

< 1 / 1 >



Abnormality Score **R 81** **L 16** Composition Category **D 10 / 10** BI-RADS Density

Index : 7  
Zoom : 51%  
W : 256 , L : 127



Abnormality Score **R 81** **L 16** Composition Category **D 10 / 10** BI-RADS Density

**maihub**

Patient Information

ER20221101175052

Sex Female

Birth Date 2022-11-01

Study Date 2022-11-01

Abnormality Score

- RCC 81 - LCC 16

- RMLO 76 - LMLO 16

Composition Category

**D** Extremely dense 10 of 10

Index : 8  
Zoom : 46%  
W : 256 , L : 127

Abnormality Score

**82** RCC

**16** LCC

**77** RMLO

**17** LMLO

**D** Extremely dense (10 of 10)

Clear AI Result

Print Send Copy

Accept

Fundus2 Fundus2 Male 0Y 0M

STD 1 X 1

IMG 2 X 1


Image List



Patient( Fundus2 , Fundus2 , M , 0Y 0M ) , Study( DOC,OP , , 2025-3-18 )

OS

OD



1-1

1-2

1000-1

Result

1000-2


Result

1001-1


Result

1002-1

Result



Index : 3  
Zoom : 61%  
W : 256 , L : 127



Index : 4  
Zoom : 61%  
W : 256 , L : 127

All Finding

- ☒ Retina Disorder
- ☒ Glaucoma
- ☐ Opacity / Artifact

OS Finding

- ☒ Retina Disorder
- ☒ Glaucoma
- ☐ Opacity / Artifact

Retinal abnormalities is detected (etc).  
Glaucoma suspicious is detected.  
No significant media opacity

OD Finding

- ☒ Retina Disorder
- ☒ Glaucoma
- ☐ Opacity / Artifact

Retinal abnormalities is detected ( , etc).  
Glaucoma suspicious is detected.  
No significant media opacity

Report

Send

Copy

Accept

Fundus2 Fundus2 Male 0Y 0M

Image List


  

OS

OD

 1-1

 1-2

 1000-1 Result

 1000-2 Result

 1001-1 Result

 1002-1 Result

Patient( Fundus2 , Fundus2 , M , 0Y 0M ) , Study( DOC,OP , , 2025-3-18 )



Index : 1  
Zoom : 60%  
W : 256 , L : 127

Index : 2  
Zoom : 60%  
W : 256 , L : 127

Tools

Eye


Heart

Status

Moderate Risk



Blood Vessel



Comment

YOUR RESULT : MODERATE RISK. According to a study, 1 in 10 people in MODERATE-RISK group will experience a cardiovascular disease event (like stroke, heart attack or other circulatory problem) within the next 10 years. A MODERATE-RISK score does not indicate that you have a cardiovascular disease nor will you definitely experience a heart attack or stroke, but it does signal the need to make changes to your lifestyle.

Report

Send

Copy


Accept

# maiLink AI Portfolio

## EASY WAY TO MEET AI

## CHEST X-RAY Diagnostic Assistance Solution

AI software that helps radiologists detect and interpret abnormalities in chest X-rays.



Detects **10** Abnormalities<sup>1)</sup>

|                       |                          |                   |
|-----------------------|--------------------------|-------------------|
| Nodule(Ndl)           | Consolidation(Csn)       | Atelectasis(Atl)  |
| Pleural effusion(PEf) | Pneumoperitoneum(Ppm)    | Pneumothorax(Ptx) |
| Fibrosis(Fib)         | Mediastinal Widening(MW) | MW/Cm Score       |
| Calcification(Calc)   | TB Analysis Score        |                   |

**Proven Efficiency** <sup>2)</sup>

**Abnormality Detection Performance**

AUROC 0.930(0.895-0.997)

**Reduces reading time**

- 13% overall (87% of cases)
- 33% for normal cases (67% of cases)

**Diagnostic Accuracy**

**97-99%**

overall **13%** ▼


Normal cases **33%** ▼

1) Abnormality Score: Indicates the likelihood (%) that an abnormal region is present.

2) Nam JG, Kim M, Park J, Hwang EJ, Lee JH, Hong JH, Goo JM, Park CM. Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs. Eur Respir J. 2021 May 20;57(5):2002061. doi: 10.1183/13993002.2002061-2020.

## Major Diseases Identifiable by Chest X-ray Abnormality Patterns


| Lung Abnormalities   | Disease                               | Abnormalities Patterns |             |               |             |
|----------------------|---------------------------------------|------------------------|-------------|---------------|-------------|
| Nodule/Mass          | Sarcoidosis                           | Interstitial Opacity   | Nodule/Mass | Consolidation | Atelectasis |
|                      | Pulmonary edema                       | Interstitial Opacity   |             | Consolidation |             |
| Consolidation        | Pneumonitis                           | Interstitial Opacity   | Nodule/Mass | Consolidation |             |
|                      | Pneumocystis pneumonia, PCP           | Interstitial Opacity   |             | Consolidation |             |
| Interstitial Opacity | Langerhans cell histiocytosis, LCH    | Interstitial Opacity   | Nodule/Mass |               |             |
|                      | Lymphangitic carcinomatosis           | Interstitial Opacity   | Nodule/Mass |               |             |
| Atelectasis          | Asbestosis                            | Interstitial Opacity   | Nodule/Mass |               |             |
|                      | Tuberculosis, miliary TB & post-TB    | Interstitial Opacity   | Nodule/Mass |               | Atelectasis |
|                      | Lung cancer                           |                        | Nodule/Mass | Consolidation | Atelectasis |
|                      | Pneumoconiosis                        | Interstitial Opacity   | Nodule/Mass |               |             |
|                      | Granulomatosis with polyangiitis      |                        | Nodule/Mass | Consolidation |             |
|                      | Cryptogenic organizing pneumonia, COP |                        | Nodule/Mass | Consolidation |             |
|                      | Mucoid impaction                      |                        | Nodule/Mass |               | Atelectasis |
|                      | Rounded atelectasis                   |                        | Nodule/Mass |               | Atelectasis |



Source : [Chest X-Ray - Lung disease Four-Pattern Approach, Robin Smithuis, Radiology Department of the Rijnland Hospital, Leiderdorp, the Netherlands](#)



Recognized by the **World Health Organization**



**Table 1. Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease, 2021**


**Tools for screening for TB**

- 9 Among individuals aged 15 years and older in populations in which TB screening is recommended, systematic screening for TB disease may be conducted using a symptom screen, chest X-ray or molecular WHO-recommended rapid diagnostic tests, alone or in combination  
*(new recommendation: conditional recommendation, very low certainty of evidence for test accuracy).*
- 10 Among individuals aged 15 years and older in populations in which TB screening is recommended, computer-aided detection software programmes may be used in place of human readers for interpreting digital chest X-rays for screening and triage for TB disease  
*(new recommendation: conditional recommendation, low certainty of evidence).*
- 11 Among adults and adolescents living with HIV, systematic screening for TB disease should be conducted using the WHO-recommended four symptom screen and those who report any one of the symptoms of current cough, fever, weight loss or night sweats may have TB and should be evaluated for TB and other diseases  
*(existing recommendation: strong recommendation, moderate certainty of evidence).*
- 12 Among adults and adolescents living with HIV, C-reactive protein using a cut-off of >5mg/L may be used to screen for TB disease  
*(new recommendation: conditional recommendation, low certainty of evidence for test accuracy).*

► The WHO (World Health Organization) Consolidated Guidelines on Tuberculosis, published in March 2021, evaluated **Lunit INSIGHT CXR** as one of the computer-aided detection (CAD) software programs that can be used in place of human readers for TB screening in individuals aged 15 years and older.

# Mammography Diagnostic Assistance Solution

Detects suspicious breast cancer lesions on mammography images, localizes potential malignant findings, and supports radiologists with probability-based analysis.



## Breast Cancer Lesion Detection

Calcification(C)


Soft-tissue lesion (Mass, M)

Breast Density

BI-RADS

### Lesion Localization

Display suspected breast cancer lesions in heatmap and contour image.



**C** Heterogeneously Dense (7 Of 10)

### Abnormality Score

The possibility of breast cancer is derived as a probability value (0-100%)



### Breast Density Assessment (BI-RADS)

Classification of breast density in 4 categories

## Superior Performance Diagnostic Assistance Accuracy<sup>1)</sup>

### Breast cancer detection Accuracy

Sensitivity with radiologists: 77.4% - Improved to 88.6% with AI

AUC **0.956**

1) Mattie Salim, Erik Wählin, Karin Dembrower, et al. External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms. JAMA Oncology. 2020


## Breast Density composition category [BI-RADS, a-b (0~10)]

[BI-RADS a (1,2) ]




Almost entirely fatty

[ BI-RADS b (3\*,4\*,5) ]




Scattered areas of  
fibroglandular  
density

[ BI-RADS c (6,7,8) ]



Heterogeneously dense

[ BI-RADS d (9,10) ]



Extremely dense

### BI-RADS 3-4 Diagnostic Support

- In moderate-density breasts (BI-RADS b), it is often difficult to distinguish between lesions and calcifications, leading to variability among physicians.
- Referring to maiLink Lunit MMG results helps assess the need for additional diagnostic work-up.  
*A reliable **“balancing tool for diagnostic support”** to reduce overdiagnosis while minimizing missed cancers (2nd Opinion).*

## Cancer Treatment Options



**Tumor size**

**T1:** 0-2 centimeters  
**T2:** 2-5 centimeters  
**T3:** >5 centimeters  
**T4:** Tumor has broken through skin or attached to chest wall



**Lymph Node Status**

**N0:** Surgeon can't feel any nodes  
**N1:** Surgeon can feel swollen nodes  
**N2:** Nodes feel swollen and lumpy  
**N3:** Swollen nodes located near collarbone



**Metastasis**

**M0:** No distant spread  
**M1:** Distant spread

### High Sensitivity for Early-Stage Breast Cancer


- High sensitivity in early stages (TNM T1, N0).
- Useful for detecting early-stage patients with high surgical potential.

*Clinically important for identifying **“treatable cancers”** at an early stage.*

1) BI-RADS: The Breast Imaging Reporting and Data System developed by the American College of Radiology (ACR) as a standardized system for reporting breast density and cancer risk assessment.

## Retinal Image Diagnostic Assistance Solution

AI solution that analyzes retinal images captured by fundus cameras to assist healthcare professionals in detecting retinal diseases.




## Detects 3 Major Retinal Diseases


*Early detection enables more effective treatment outcomes  
(when identified before symptom onset)*




Normal



Diabetic Retinopathy (DR)



Age-related Macular Degeneration (AMD)



Glaucoma (GLC)

## Diagnostic Optimization

Trained on over 70,000 fundus image  
Mean AUC  $\geq 0.85$  across key disease types

- AMD Sensitivity 0.75 / Specificity 0.87
- DR Sensitivity & Specificity  $\geq 0.81$
- GLC Sensitivity 0.70 / Specificity 0.75

### Fast Analysis Time

Deliver AI results within 3–5 sec

AUC **0.85**

Analysis Time **3sec**

Fundus

John Doe's Retinal Screening AI Report

Date of Birth 1992-03-07

Sex M

Examination Date 2024-07-01

Your Retinal Images

Right Eye

Left Eye

Retinal Health Analysis Results

Right Eye Findings

According to the AI analysis, **no signs of vision-threatening retinal diseases (DR, AMD, GLC)** were detected in your right eye image.

Left Eye Findings

According to the AI analysis, signs of **glaucoma** were detected in your left eye.

Optic Disc: The point where the optic nerve exits the eye. This area contains no photoreceptor cells, resulting in a natural blind spot in the field of vision.

Macula: The central area of the retina where photoreceptor cells are densely packed, enabling sharp and precise vision. These cells are connected to nerve fibers that transmit visual signals to the brain.

We recommend visiting an specialist as soon as possible for accurate diagnosis, further testing, and appropriate treatment.

ARK

Fundus

Major Retinal Diseases to Watch For

The retina plays a critical role in vision, and any damage to it can lead to permanent vision loss or blindness. Photoreceptor cells in the retina cannot regenerate once damaged, early detection and timely treatment are essential.

Age-Related Macular Degeneration (AMD)

Degeneration in the central retina (macula) that causes vision loss. Age-Related Macular Degeneration affects the central part of the retina, which plays a key role in vision. As the condition progresses, it can cause vision loss and lead to blindness if left untreated. Aging is the main risk factor, so regular eye screenings and good health habits are important for prevention.

An eye exam is recommended if you notice these symptoms

- A dark spot or blank area in the center of vision.
- Sudden and significant vision loss.

Diabetic Retinopathy (DR)

Diabetic retinopathy is a complication of diabetes that affects the retina. It is a leading cause of vision loss in people with diabetes. Regular eye exams are essential for people with diabetes.

An eye exam is recommended if you notice these symptoms

- Blurry vision.
- Double vision.
- Sudden changes in vision.

Glaucoma (GLC)

Vision loss caused by damage to the optic nerve. Glaucoma is a condition where pressure inside the eye is too high, which can damage the optic nerve and lead to vision loss.

An eye exam is recommended if you notice these symptoms

- Recurring headaches.
- Sudden vision loss.

Cataract (CAT)

Visual loss caused by clouding of the lens. Cataracts are an age-related condition that can be successfully treated with surgery.

An eye exam is recommended if you notice these symptoms

- Blurry vision.
- Decreased vision at night.

Regular screenings and early diagnosis are key to preventing retinal diseases.

A fundus examination uses a fundus camera to capture images of the retina, including its blood vessels and the color and thickness of the optic nerve, through the pupil. A single fundus exam can detect a variety of retinal diseases. Adults over the age of 40 are advised to undergo annual screenings.

|                                        | Main Causes                                                                                                                       | Diagnostic Methods                                                                                                   | Screening Recommendations                                                                                                              |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Age-related Macular Degeneration (AMD) | Aging, smoking, family history of cardiovascular disease, excessive UV exposure                                                   | Fundus examination, Fluorescein angiography, Optical Coherence Tomography                                            | Fundus examination is recommended starting at age 40 for individuals with a family history; routine screenings from age 50             |
| Diabetic Retinopathy (DR)              | Diabetes, aging, family history, high myopia                                                                                      | Fundus examination, Fluorescein angiography, Optical Coherence Tomography, Ultrasound, Electroretinography           | Annual fundus exams are recommended for diabetic patients; regular screenings for individuals over 40 with cardiovascular risk factors |
| Glaucoma (GLC)                         | High intraocular pressure, insufficient blood supply, family history, age, hypertension, diabetes, cardiovascular disease, myopia | Fundus examination, Visual acuity test, Intraocular Pressure measurement, Optic nerve examination, Visual field test | Every 2-3 years for individuals aged 40-60; every 1-2 years for those over 60                                                          |
| Cataract (CAT)                         | Aging, family history, eye injury, diabetes, prolonged steroid use, excessive UV exposure                                         | Visual acuity test, Fundus examination, Slit-lamp examination, Refraction test                                       | Every 2-3 years for individuals over 40; annually or every 1-2 years if symptoms or risk factors are present                           |

9 Lifestyle Habits for Maintaining Eye Health

- Have your child's vision checked before age 4 to detect amblyopia early.
- Control diabetes, hypertension, and high cholesterol to lower the risk of cataracts and diabetic retinopathy.
- Quit smoking to reduce the risk of AMD and cataracts.
- Wear sunglasses or hats to protect your eyes from UV damage.
- Use appropriate eye protection during work or sports to prevent eye injuries.
- Individuals over the age of 40 should receive regular eye exams for early detection of eye conditions.
- Consult an eye specialist before using or managing contact lenses.
- Maintain a comfortable indoor environment and limit prolonged screen time to prevent dry eyes and inflammation.
- Limit prolonged near work and maintain adequate indoor lighting to help prevent myopia.

## Early Detection of Vision-Threatening Diseases

Identifies the lesion sites of three major retinal diseases even before noticeable symptoms appear, providing precise and visualized reports.

*Helps secure the "golden time" for early treatment and intervention.*

## High Clinical Applicability

Co-designed by developers and clinical experts to ensure diagnostic reliability. Tailored for real-world ophthalmic practice, providing medically interpretable and clinically applicable AI results.

## Validated Through Multi-Institutional Use

Verified across various care settings—including health check-up centers, internal medicine, family clinics, and public health centers. At certain hospitals, screening rates increased by over 56% <sup>1)</sup> after Wisky adoption.

*Enhances screening coverage and improves clinical efficiency.*

## Personalized Eye Health Report

Delivers results and lifestyle guidance through maiReport, allowing users to review and manage their eye health conveniently.


1) 3대 망막질환 1분 이내 판독, 국내 외 사업 확장 속도, 서울경제신문 조원진 기자 배포 자료 (3대 망막질환 1분 이내 판독 '아크'...국내·외 사업 확장 속도[부산특특] | 서울경제)

maihub Company Introduction

Copyright (C) maihub Corp. All rights reserved.


## Retinal Image Diagnostic Assistance Solution

AI solution that analyzes retinal structure and blood vessels to indicate the risk of cardiovascular disease.



## High Usability Low testing burden

*Predicts cardiovascular disease risk within 5 years*  
*Comparable to cardiac CT performance*



## Superior Performance Disease Risk Prediction<sup>1)</sup>

### Proven CVD risk prediction

- 5-year prospective cohort study with 1,106 participants
- Results highly correlated with Coronary Artery Calcification (CAC) scores from cardiac CT
- Outperforms brachial-ankle Pulse Wave Velocity

Comparable to **CAC**

**baPWV** ▲

### Efficient Screening Process

End-to-end prediction from retinal imaging to report generation

Takes only **3min**

1) Deep-learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs Rim, Tyler Hyungtaek et al. The Lancet Digital Health, Volume 3, Issue 5, e306 - e316  
2) 망막 촬영 기반 심혈관 위험 평가 의료기기 S/W "DrNoon for CVD"의 유효성 검증: 단일기관, 후향적, 확증 임상시험. 2022

# Knee X-ray based Osteoarthritis Assessment Solution

AI solution that assists healthcare professionals in diagnosing osteoarthritis by classifying KL grades




## High Accuracy Comprehensive OA Evaluation

Quantitative analysis of Joint Space Narrowing comparison from the normal group.


Detects Femur/Tibia, Osteophyte

Displays KL Grade  
KL0/1 ~ KL4

## Reference Standard Alignment <sup>2)</sup>



AUC **0.93**



Increased Accuracy **31%** ▲

1) KL(Kellgren Lawrence Classification of Osteoarthritis, 켈그렌-로렌스 분류) 등급은 0~4까지의 5 단계로 X-ray에서 보이는변형 정도(골극, 관절강 협소, 골변형 등)를 기준으로 퇴행성 관절염의 중증도를 판단하는 등급

2) Yoon JS, Yon CJ, Lee D, et al. Assessment of a novel deep learning-based software developed for automatic feature extraction and grading of radiographic knee osteoarthritis. BMC Musculoskelet Disord 24, 869 (2023). <https://doi.org/10.1186/s12891-023-06951-4>

## Hand X-ray based Bone Age Assessment Solution

AI software that supports clinicians in evaluating bone age from hand X-rays based on the Greulich–Pyle (GP) method, providing automated bone age estimation and comparative growth prediction.



## Fast & Accurate Analysis (within 5-10 sec)

Bone age analysis based on GP Atlas

Height prediction using genomic data

3 most likely bone age suggestions

Provide bone age report

Patient history comparison

Provide reference image

## High Consistency

**Reduced reading time<sup>1)</sup>**  
(from 180 min → 108 min per 200 cases)

**Increased reading accuracy**  
(from 49.5 % → 57.5 %)

**High consistency with Radiologists<sup>2)</sup>**  
0.995 (95% CI: 0.993–0.996)

**40 %** ▼


**16 %** ▲

**ICC 0.995**

1) Kim JR, Shim WH, Yoon HM, Hong SH, Lee JS, Cho YA, Kim S. Computerized Bone Age Estimation Using Deep Learning Based Program: Evaluation of the Accuracy and Efficiency. AJR Am J Roentgenol. 2017 Dec;209(6):1374-1380. doi: 10.2214/AJR.17.19224. Epub 2017 Sep 13.  
2) Özmen E, Atalay HÖ, Uzer E, Veznikli M. A comparison of two artificial intelligence-based methods for assessing bone age in Turkish children: BoneXpert and VUNO Med-Bone Age. Diagn Interv Radiol. undefined undefined;undefined(undefined):-. doi:10.4274/dir.2024.242790.


# AI-Driven Consistency

Streamlining diagnosis with expert-level precision




Dataset (35,000) + Dataset (15,000)

50,000  
Training Data



- Stable performance across diverse populations using both domestic and international datasets
- Suggests up to **Top 3 most likely bone age groups** based on the Greulich–Pyle (GP) method.


## BoneAge Report



- Enhances clinical satisfaction by providing a **personalized growth report** for patients and parents.
- Results are viewable through the **maiReport** mobile app.

## Chest CT based Lung Nodule Diagnosis Solution

AI software that assists healthcare professionals in detecting and analyzing lung nodules on chest CT images



### Comprehensive Nodule Analysis

Solide Nodule  
Detection


Nodule Analysis  
(Size, Morphology)

Nodule Classification  
(Solid, Calcified, Others)

Lung-RADS  
Classification

VDT(Volume Doubling  
Time) Calculation

### High Diagnostic Accuracy




Validated through local clinical studies  
Sensitivity 97%, Specificity 76%

AUC **0.93**

## CT based Coronary Artery Calcification Analysis Solution

AI software that detects and quantifies coronary artery calcification (CAC) from CT images to assist clinicians in evaluating the presence and severity of cardiovascular disease



## Accurate Quantification

### CAC Agatston Score

#### Agatston Score

| Artery | AS [1] | VS [2] (mm <sup>3</sup> ) | MS [3] (mg CaHA) | Area [4] (mm <sup>2</sup> ) |
|--------|--------|---------------------------|------------------|-----------------------------|
| LM     | 41     | 31                        | 7.6              | 14.1                        |
| LAD    | 1175   | 908                       | 295.6            | 301.1                       |
| LCX    | 463    | 361                       | 93.4             | 137.2                       |
| RCA    | 728    | 577                       | 143.4            | 210.2                       |
| Total  | 2407   | 1877                      | 540.0            | 662.6                       |

CAC threshold 130 HU  
Mass conversion factor 0.743

[1] Agatston Score  
[2] Isotropic Interpolated Volume  
[3] Equivalent Mass  
[4] Area Measured In

Left Main (LM)

Left Anterior  
Descending (LAD)

Left Circumflex (LCX)

Right Coronary Artery  
(RCA)

## High Diagnostic Precision <sup>1)</sup>

Lesion detection & Classification  
Consistency

87%

Agatston Score Consistency

95%

AI 진단 정확도 **99.2 %**

1) Marleen Vonder, Sunyi Zheng, Monique D.Dorrius, Carlijn M.van der Aalst, Harry J.de Koning, Jaeyoun Yi, Donghoon Yu, Jan Willem C. Gratama, Dirkjan Kuijpers, Matthijs Oudkerk, "Deep learning for automatic calcium scoring in population based cardiovascular screening", JACC: Cardiovascular Imaging 15 (2021), pp.366-367, <https://doi.org/10.1016/j.jcmg.2021.07.012>

## Cerebral Aneurysm Risk Analysis Service

Based on health checkup results, this service automatically estimates the relative risk of cerebral aneurysm and provides follow-up management solutions.



### What is a Cerebral Aneurysm?

A cerebral aneurysm is a cerebrovascular disorder where a blood vessel in the brain bulges like a balloon. It has similar properties as balloons, which means that once an aneurysm forms the size continues to increase, thus developing a risk of rupture. A cerebral aneurysm rupture leads to subarachnoid hemorrhage, which is a type of cerebral hemorrhage with the highest death and disability rate. The most definite way of preventing subarachnoid hemorrhage is receiving an appropriate screening before the aneurysm bursts and treating the aneurysm via two types of treatments, clipping or coiling.

The purpose of our AI algorithm is to encourage all examinees to take care of their health on a daily basis by analyzing and displaying the statistical similarity between the examinee's medical exam results and cerebral aneurysm patients. At the end of the report, a guide on items that require regulation for a healthier life is provided.

### Analysis Results TESTMAIHUB (Male, 46 yo)



### Incidence and Prevalence rate based on National Standard Risk Level

|                                                                                                                       | Lowest Risk | Lower Risk | Average Risk | Higher Risk | Highest Risk |
|-----------------------------------------------------------------------------------------------------------------------|-------------|------------|--------------|-------------|--------------|
| <b>Prevalence</b><br>The probability of having a cerebral aneurysm already                                            | 0.17%       | 2.12%      | 2.37%        | 4.00%       | 6.44%        |
| <b>Incidence</b><br>The probability of occurrence within the next 3 years even if there are no cerebral aneurysms now | 0.02%       | 0.09%      | 0.21%        | 0.37%       | 0.80%        |

Analysis Date: Jul 23 2025 2 / 4 TESTMAIHUB (Male, 46 yo)




### Factor-specific Impact Analysis

TESTMAIHUB (Male, 46 yo)

The graph below displays medical examination items that statistically have an effect on the incidence of cerebral aneurysms. The red bars indicate items that increase the statistical likelihood of cerebral aneurysms and the blue bars indicate items that decrease the statistical likelihood.

Some examination items (Fam. hx, Diabetes) have not been provided, which may result in inaccuracies in the analysis results.



### The following instructions are recommended to reduce the incidence of cerebral aneurysms:

- ☐ Consultation for treatment is needed for your high glucose levels (300).
- ☐ Quitting smoking is strongly recommended.
- ☐ Regulate your Diastolic BP from (130) to (76).
- ☐ Regulate your LDL from (299) to (134).
- ☐ Regulate your Systolic BP from (300) to (119).
- ☐ Regulate your Total cholesterol from (300) to (199).
- ☐ Regulate your Triglyceride from (600) to (150).
- ☐ Regulate your Waist circumference from (120) to (85).

Analysis Date: Jul 23 2025 3 / 4 TESTMAIHUB (Male, 46 yo)

## Cerebral Aneurysm Risk Prediction

Cerebral aneurysm



Subarachnoid Hemorrhage, SAH

aneurysm, bleeding



Classification by risk score:

- **Lowest Risk: 0–19**
- **Lower Risk: 20–39**
- **Average Risk: 40–59**
- **Higher Risk: 60–79**
- **Highest Risk: 80–100**

## High Efficiency Selective Screening<sup>1)</sup>

Clinically meaningful performance<sup>2)</sup>  
(AUROC ≥ 0.75)

High Risk Aneurysm Classification  
Detection Probability in Neuroimaging

AUC **0.77**

Overall **80%**  
detection rate

1) Heo, J., Park, S.J., Kang, S.H. et al. Prediction of Intracranial Aneurysm Risk using Machine Learning. Sci Rep 10, 6921 (2020). <https://doi.org/10.1028/s41598-020-63906-8>

2) ANRISK is not a medical device. It is a statistical analysis software that uses epidemiological data and health checkup results to provide intracranial aneurysm risk analysis.

# maLINK ANRISK Cerebral Aneurysm Risk Analysis Service Based on Health Check-Up

## ◆ Risk Score

- Indicates your risk rank out of 100 individuals.
- A score of **100** means the highest risk, while **0** indicates the lowest risk.

## ◆ Risk Grade (5 Levels)

Risk scores are categorized into five levels:


### Analysis Results

TESTMAIHUB (Male, 46 yo)



| Risk Grade   | Risk Score Range | Prevalence | Relative Risk (vs. Very Low) | Incidence | Relative Risk (vs. Very Low) |
|--------------|------------------|------------|------------------------------|-----------|------------------------------|
| Lowest Risk  | 0–19             | 0.17%      | —                            | 0.02%     | —                            |
| Lower Risk   | 20–39            | 2.12%      | 12.5x                        | 0.09%     | 5.5x                         |
| Average Risk | 40–59            | 2.37%      | 13.9x                        | 0.21%     | 12.8x                        |
| Higher Risk  | 60–79            | 4.00%      | 23.5x                        | 0.37%     | 23.3x                        |
| Highest Risk | 80–100           | 6.44%      | 37.5x                        | 0.80%     | 49.9x                        |

# maiLink ANRISK Cerebral Aneurysm Risk Analysis Service Based on Health Check-Up



The following instructions are recommended to reduce the incidence of cerebral aneurysms:

- ☐ Consultation for treatment is needed for your high glucose levels (300).
- ☐ Quitting smoking is strongly recommended.
- ☐ Regulate your Diastolic BP from (150) to (76).
- ☐ Regulate your LDL from (299) to (114).
- ☐ Regulate your Systolic BP from (300) to (119).
- ☐ Regulate your Total cholesterol from (500) to (199).
- ☐ Regulate your Triglyceride from (600) to (150).
- ☐ Regulate your Waist circumference from (120) to (85).

## Recommended Health Targets

- Based on the analysis, ANRISK™ suggests customized health targets that can help reduce your risk.
- Fixed factors like age, gender, or family history are excluded, focusing only on things you can change.
- The system calculates the most effective targets for each person, depending on how each factor contributes to their overall risk.
- Not everyone will receive the same number of targets—and in some cases, no targets may be suggested if lifestyle changes wouldn't impact the score meaningfully.



## How Much Your Risk Can Improve

- If you achieve all the recommended health targets, ANRISK™ shows how much your risk score could improve.

# maLINK ANRISK Cerebral Aneurysm Risk Analysis Service Based on Health Check-Up



Sentinel AI Algorithm for Cerebral Aneurysm Risk Assessment

## ANRISK® Risk Assessment Report for Cerebral Aneurysm

TESTMAIHUB (Male, 46 yo)

Examination Date: Jul 23 2025

Analysis Date: Jul 23 2025



### What is a Cerebral Aneurysm?

A cerebral aneurysm is a cerebrovascular disorder where a blood vessel in the brain bulges like a balloon. It has similar properties as balloons, which means that once an aneurysm forms the size continues to increase, thus developing a risk of rupture. A cerebral aneurysm rupture leads to subarachnoid hemorrhage, which is a type of cerebral hemorrhage with the highest death and disability rate. The most definite way of preventing subarachnoid hemorrhage is receiving an appropriate screening before the aneurysm bursts and treating the aneurysm via two types of treatments, clipping or coiling.

The purpose of our AI algorithm is to encourage all examinees to take care of their health on a daily basis by analyzing and displaying the statistical similarity between the examinee's medical exam results and cerebral aneurysm patients. At the end of the report, a guide on items that require regulation for a healthier life is provided.

### Analysis Results

TESTMAIHUB (Male, 46 yo)



### Incidence and Prevalence rate based on National Standard Risk Level

|                                                                                                                       | Lowest Risk | Lower Risk | Average Risk | Higher Risk | Highest Risk |
|-----------------------------------------------------------------------------------------------------------------------|-------------|------------|--------------|-------------|--------------|
| <b>Prevalence</b><br>The probability of having a cerebral aneurysm already                                            | 0.17%       | 2.12%      | 2.37%        | 4.00%       | 6.44%        |
| <b>Incidence</b><br>The probability of occurrence within the next 5 years even if there are no cerebral aneurysms now | 0.02%       | 0.09%      | 0.21%        | 0.37%       | 0.80%        |

Copyright 2025. TALOS Corp. all rights reserved. Modification and copying of all content, includin

Analysis Date: Jul 23 2025

1 / 4




### Factor-specific Impact Analysis

TESTMAIHUB (Male, 46 yo)

The graph below displays medical examination items that statistically have an effect on the incidence of cerebral aneurysms. The red bars indicate items that increase the statistical likelihood of cerebral aneurysms and the blue bars indicate items that decrease the statistical likelihood.

Some examination items (Fam. hx. Diabetes) have not been provided, which may result in inaccuracies in the analysis results.



### The following instructions are recommended to reduce the incidence of cerebral aneurysms:

- ☐ Consultation for treatment is needed for your high glucose levels (300).
- ☐ Quitting smoking is strongly recommended.
- ☐ Regulate your Diastolic BP from (150) to (76).
- ☐ Regulate your LDL from (299) to (114).
- ☐ Regulate your Systolic BP from (300) to (119).
- ☐ Regulate your Total cholesterol from (500) to (199).
- ☐ Regulate your Triglyceride from (600) to (150).
- ☐ Regulate your Waist circumference from (120) to (85).

Analysis Date: Jul 23 2025

3 / 4

TESTMAIHUB (Male, 46 yo)



If you manage according to the goals provided earlier, the national standard risk of cerebral aneurysm for you, TESTMAIHUB, could be improved as shown below.



- The purpose of this program is not medical, such as the diagnosis or treatment of diseases, but simply to encourage examinees to take care of their health in their daily lives. This software analyzes the statistical similarity between the examinee and cerebral aneurysm patients through an AI algorithm by using health examination results. The analysis is visualized as a comprehensible graph that displays the current status of the examinee and levels that need to be regulated on a daily basis. The diagnosis, screening and treatment of cerebral aneurysms must be provided by a healthcare specialist.
- The "risk level" used in this report is defined by the statistical degree of similarity between the examinee and the health screening results of cerebral aneurysm patients.
- The "analysis" used in this report is a process by which health screening data is used to calculate the statistical similarity between the examinee and cerebral aneurysm patients.
- The risk groups used in this report is based on the study "Prediction of Intracranial Aneurysm Risk using Machine Learning. Sci Rep 10, 6921 (2020)", which can be accessed at <https://doi.org/10.1038/s41598-020-63966-6>.
- The recommended target levels displayed in this report are statistical calculations. The diagnosis and prescription of a healthcare provider must precede the appropriate follow-up care plan.
- This program defines smoking status based on the use of regular cigarettes (combustible tobacco) for the risk analysis.


Analysis Date: Jul 23 2025

4 / 4

TESTMAIHUB (Male, 46 yo)

## Disease Risk Prediction based on Health Checkup Results

Based on past health checkup results, this service predicts disease occurrence risk, provides health age, and delivers a comprehensive health analysis report.



## Prediction of 10 Major Diseases



Health Age  
estimation

10-Year  
Mortality Risk  
Prediction

Comparative Analysis with Age-  
and Gender-Matched Groups

## High Accuracy Preventive Healthcare with AI<sup>1)</sup>

Lifestyle-related disease risk prediction  
 Average AUC for 10 diseases:  
**0.90 (0.81–0.93)**

**AUC 0.93**

<sup>1)</sup> (Area Under Curve): A standard performance metric for AI prediction models. Disease-specific performance validated by Selvas AI's internal evaluation.  
 Diabetes: 0.93, Gastric Cancer: 0.85, Stroke: 0.87, Dementia: 0.88, Liver Cancer: 0.84, Stomach Cancer: 0.82, Lung Cancer: 0.81, Colon Cancer: 0.91, Breast Cancer: 0.90, Prostate Cancer: 0.84


## 10 Major Disease Risk Prediction Service Based on Health Check-Up



### AI-Based 10 Major Disease Prediction Report

Prediction of 10 Major Diseases  
using Artificial Intelligence

Patient Name MAIHUB  
Birthdate 1979-03-25  
Examination Date 2025-07-23  
Hospital MAIHUB



### Summary of Health Age and Check-Up Results

AI analyzes your overall health status from multiple angles, providing insights into your **biological (health) age** and a **comprehensive risk assessment** for disease development.

### Risk Assessment for 10 Major Conditions

Covers the risk of developing 10 key diseases related to chronic conditions and lifestyle habits, with a **4-year prediction of disease incidence and risk level** provided in one report.



## Bone trauma Diagnostic Assistance Solution

AI solution that detects fractures, dislocations, fissures, and bone lesions (excluding the skull and spine) to improve diagnostic sensitivity and accuracy.



## High Accuracy Improved detection performance

- **+16%** In Sensitivity
- **–30%** Missed Fractures

## Outstanding Efficiency

- Average reading time reduced by **6.3 seconds** <sup>2)</sup>
- Improved both Sensitivity & Specificity (Radiology 2022)

## Reduced Workload

- **–27%** Reduction length of stay for positive patient (Rennes Univ study) <sup>3)</sup>
- Supports non-radiology specialists with expert-level diagnostic assistance

**40M+**

Exams per year

**2500+**

Public and private institutions

**30+**


Clinical studies

1) Guermazi et al. Improving radiographic fracture recognition performance and efficiency using artificial intelligence. Radiology 2022  
 2) Aubry et al. Added value of an artificial intelligence solution for fracture detection in the radiologist's daily trauma emergencies workflow. Diagnostic and Interventional Imaging 2022  
 3) independent study by Rennes University Hospital (2020–2022, ED cohort)



# 96 %

Osteoporosis  
Detection Accuracy  
Compared to DXA



## Clinical Research In Wanfang Hospital

|              |                         |
|--------------|-------------------------|
| Participants | 3,460 samples aged 50 ↑ |
| Indicators   | DXA Report              |
| Accuracy     | <b>96.4%</b>            |

## Enhancing Accessibility with X-ray

- Enables faster analysis, allowing for more patient screenings
- Can be effectively used in regions with limited medical access

## Fast and Accurate Bone Density Analysis

- Detects osteoporosis, bone mineral density (BMD), and fracture risk in just 6 seconds
- Automated labeling and data visualization improve efficiency for medical professionals

## Intuitive and Easy-to-Understand Reports

- Visually enhanced reports help patients understand their results easily
- Provides both T-Score and Z-Score for osteoporosis assessment

## Simple Osteoporosis Screening with DXA-Level Accuracy

### DXA

- High Cost
- Time-consuming  
(20 mins (24 patients in 8 hrs))
- Unfriendly for Fracture Patients  
(Need to hold the specific pose to do the test)

### Hip X-ray Diagnostic AI

- Accuracy comparable to DXA (96.4%)
- Shorter exam time  
6 seconds (about 160 patients in 8 hrs)
- Follows WHO osteoporosis diagnostic criteria
- Cost-effective

# Thank you.

## EASY WAY TO MEET AI